Apr 22, 2011 2:29 PM GMT
Personally I think they should deregulate and legalize it all.
The American Independent has previously reported on the growing corporatization of the incipient medical marijuana industry at a time when medical marijuana dispensaries scrabble to hold on to their businesses in the face of a multi-pronged federal crackdown. But there are signs afoot that it just may become ever more corporate if a Big Pharma push to get the U.S. Food and Drug Administration to recognize a cannabis-derived drug is successful.
Last week, British prescription drug manufacturer GW Pharmaceuticals announced a licensing agreement with drug giant Novartis, maker of Ritalin and Excedrin, to begin selling GW’s drug Sativex in markets across Asia, Africa, Oceania and the Middle East. The medication is already available in Britain, where it’s produced and marketed by Bayer, and in Canada and Spain. It’s on the market in those countries as a liquid that patients spray under the tongue and is prescribed primarily for sufferers of multiple sclerosis and cancer.
[...] Can pharmaceutical clout bring FDA approval?
So how are pharmaceutical companies looking to succeed where medical marijuana dispensaries are failing in getting marijuana recognized by the FDA without any federal agencies breathing down their necks? One answer could be in the clout the industry holds in Washington.
The pharmaceutical industry is far and away the biggest spender on federal lobbying. Between 1998 and 2010, Big Pharma spent more than $2 billion sending lobbyists to the capital to fight for industry-friendly legislation and regulations. This is over half a billion more than the amount spent in the same period by pharmaceuticals’ closest competitor, the insurance industry, and nearly twice what oil and gas companies spent. The medical marijuana lobby, less than six months old and consisting almost entirely of Steve Fox (backed by NCIA director Aaron Smith and a handful of dispensary owners and enthusiasts), could never compete.
All this puts the surging federal clampdown on medical marijuana in a new light. As nationwide support for medical marijuana reaches record levels, it may just be the pharmaceutical industry that rides that wave of support to huge profits.